Fate of new cancer drug is uncertain in Netherlands, as institute deems it too costly

The future of a newly licensed drug to treat lung cancer hangs in the balance in the Netherlands after the country’s National Health Care Institute (ZIN) found that its cost would be €134 000 (£97 000; $150 000) per quality adjusted life year (QALY) saved. This would be the first time in the Neth...